科拓生物 (300858.SZ) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	373.3M	365.9M	302.8M	299.2M	369.2M
Cost of Revenue	185.3M	177.5M	126.4M	135.9M	177.3M
Gross Profit	188.0M	188.5M	176.4M	163.3M	191.9M
Operating Expenses
R&D Expense	36.6M	35.7M	36.3M	34.2M	22.1M
SG&A Expense	—	—	—	—	—
General & Admin Expense	35.6M	33.0M	31.4M	24.1M	29.6M
Selling & Marketing Expense	37.2M	38.3M	36.5M	33.9M	27.2M
Other Expenses	—	—	—	—	—
Total Operating Expenses	96.3M	92.9M	85.0M	73.7M	79.5M
Cost and Expenses	281.7M	270.3M	211.4M	209.6M	256.8M
Operating Income (EBIT)	96.3M	104.6M	109.5M	102.6M	127.6M
Non-Operating
Interest Income	—	—	—	—	—
Interest Expense	—	—	—	—	—
Net Interest Income	—	—	—	—	—
Other Non-Op Income/Expense	—	—	—	—	—
Non-Operating Income (excl Interest)	—	—	—	—	—
EBT (Pre-Tax Income)	95.5M	103.8M	108.8M	102.0M	125.7M
Income Tax Expense	6.4M	9.3M	14.5M	8.6M	15.8M
Bottom Line
Net Income	89.1M	94.5M	94.4M	93.5M	109.9M
Earnings from Cont. Ops	89.1M	94.5M	94.4M	93.5M	109.9M
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	89.1M	94.5M	94.4M	93.5M	109.9M
Per Share
Basic EPS	CN¥0.34	CN¥0.36	CN¥0.36	CN¥0.35	CN¥0.49
Diluted EPS	CN¥0.34	CN¥0.36	CN¥0.36	CN¥0.35	CN¥0.49
Revenue Per Share	CN¥1.50	CN¥1.39	CN¥1.16	CN¥1.12	CN¥1.65
Shares
Basic Shares Outstanding	249.2M	262.6M	262.1M	267.1M	224.3M
Diluted Shares Outstanding	249.2M	262.6M	262.1M	267.1M	224.3M
Profitability Metrics
EBITDA	—	138.3M	135.0M	121.4M	144.4M
D&A	—	33.7M	25.5M	18.8M	16.8M
EBIT	—	—	—	—	—

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026